Roquette is a French-based family owned company which produces more than 650 by-products from the starch extracted from corn, wheat, potatoes and peas. Founded and headquartered in Lestrem, France in 1933 by the brothers Dominique and Germain Roquette, Roquette has grown to become the leader in starch production in Europe and the number four ranked producer of starch worldwide. It is also the leader in the production of Polyols worldwide (substances derived from food compounds). Roquette employs more than 6,600 people globally and achieved a turnover of over 2,5 billion euros in 2011.

Since the establishment of Sunkyung Textiles in 1969, SK Chemicals has grown through continuous change and innovation into a chemical and life sciences enterprise representing South Korea. SK Chemicals’ new mission statement says, "They enhance human health and protect the Earth’s environment" and they have reorganized their business structure to focus on the two large sectors of green chemicals and life sciences. Providing distinguished chemical and life sciences products and solutions based on the world's highest technology standards, SK Chemicals is recognized as a leading global company of environmentally-friendly materials and total healthcare solutions. Their green chemical business is steadily progressing as a leading global company in the environmentally-friendly materials business by using the world’s best technology, knowledge, and production facilities. To achieve this goal, SK Chemicals has selected four new core areas of business: bio-materials, composites, high-performance materials, and energy saving materials while continuing a commitment to R&D activities.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Part of Arkema SA, Arkema France SA is a company headquartered in Colombes, France, that manufactures and supplies vinyl products, industrial chemicals and performance products. Thierry le Hénaff is the CEO, in this role since 2004.

Del Mar Pharmaceuticals (BC) Ltd., part of Kintara Therapeutics, Inc., is a company headquartered in Vancouver, BC, Canada, that provides drug development services. It was founded by William James Garner, Dennis M. Brown and Jeffrey A. Bacha. Jeffrey A. Bacha is the current CEO, occupying that position since 2010. Kintara Therapeutics, Inc. acquired Del Mar Pharmaceuticals (BC) Ltd. on January 25, 2013 for $0.65 million.

A global leader in more than 120 countries on five continents with 29,000 team members and over 250,000 customer contacts per day, investing over $350M per year in R&D to launch over 60 innovations annually. - This is Hilti. "We create enthusiastic customers and build a better future!" by living our clear values of integrity, the courage to embrace change, teamwork and commitment. This forms the basis for Hilti’s unique corporate culture. Reciprocal tenets of openness, honesty and tolerance apply to team members, partners and suppliers alike.This is the foundation for our long-term financial success - success that we combine with corporate responsibility and environmental protection. Become a part of our successful organization! We are always searching for people who want to move things forward, and bring in their own perspectives and innovative ideas. We continuously invest in the further development of our team members by providing them opportunities across functional and geographical borders as well as to pursue a career as an expert.

International food processor

Dr. Willmar Schwabe GmbH & Co. KG engages in research, development, production, and distribution of generic drugs derived from plants. It offers herbal medicinal products, which include medicines for the treatment of memory loss, lack of concentration, anxiety, bronchitis, muscle and joint pain, enlarged prostate, neurodermatitis, eczemas, and sleeping problems. The company was founded by Willmar Schwabe in 1866 and is headquartered in Karlsruhe, Germany.

PolyPlexx, LLC is a West Virginia member managed LLC. PolyPlexx is headquartered in Building 740 of the West Virginia Regional Technology Park in South Charleston, West Virginia. To date, PolyPlexx has created a technology platform consisting of three commercially available polymer formulations. A U.S. patent, a European patent and a World Patent (WPTO) have been issued for the technology. These polymers are recognized as having significant utility in a variety of commercial applications requiring transparency and improved impact resistance.

Solvay Specialty Polymers is a science company that develops solutions that address social, environmental, and industrial challenges. The company's products designed to perform in the harshest environments, with the specific combination of properties required for exceptional heat resistance and chemical inertness, strength, and toughness, lightweight and design flexibility, biocompatibility, and many more. It materials are used in the most demanding industries, including deep-sea exploration and implantable spinal devices.

A et A-Mäder SA operates as a holding company, with interest in the manufacture and sales of industrial paints, special composite coating, resins, and gel coats. Through its subsidiaries, the firm caters to the railway, automotive, aeronautics, cosmetics, electro-technical, gas, food production, public works, and other related sectors. The company was founded in 1993 and is headquartered in Villeneuve d'Ascq, France.

Covestro Deutschland AG engages in the production and distribution of polymers. It also sells paints and adhesive raw materials. The company was founded on April 8, 2002 and is headquartered in Leverkusen, Germany.

Allnex Belgium SA engages in the manufacturing of coating resins, additives and adhesives. The firm produces adhesives used in inks, coatings and powder paints. Its products include radiation-cured resins, powder coating resins, liquid coating resins, water-borne resins, amino resins and solvent based resins. The company is headquartered in Drogenbos, Belgium.

Pfizer Manufacturing Deutschland GmbH, part of Pfizer Inc., is a company headquartered in Berlin, Germany, that develops and distributes pharmaceutical products. Axel Glatz is the current CEO of the firm. On October 01, 2014 R-Pharm CJSC acquired Pfizer Manufacturing Deutschland GmbH from Pfizer Inc.\nThe company says this about itself: For over 160 years, the Pfizer name has been synonymous with state-of-the-art pharmaceuticals research and development. More than 10,000 researchers and around 97,000 employees worldwide at Pfizer develop and manufacture vaccines and medicines to prevent, cure or alleviate diseases. Our research focuses on cancer, pain, inflammatory diseases and disorders of the central nervous system. Pfizer currently employs more than 2,000 people at three locations in Germany��Berlin, Freiburg and Karlsruhe. A high-performance hub in Pfizer's global manufacturing and sales network, the Freiburg plant produces six billion tablets a year, alongside other products. Putting its hallmark know-how, innovation and quality into action, this facility has pursued a green strategy and engaged in sustainable, resource-sparing practices for many years. It makes solid drug forms to Industry 4.0 standards using continuous manufacturing technology. CMT sequences individual steps to achieve a smooth, uninterrupted manufacturing flow from incoming raw materials to the outgoing finished product. With this innovative process, the Freiburg factory is a true technology pioneer in the pharmaceutical industry.

Kia Motors Corporation, commonly known as Kia Motors.(Korean: 기아자동차; Hanja: 起亞自動車, IPA: [ki.a], lit. "Kia automobile"; stylized as KIɅ), headquartered in Seoul, is South Korea's second-largest automobile manufacturer, following the Hyundai Motor Company, with sales of over 3.3 million vehicles in 2015. As of December 2015, the Kia Motor Corporation is minority owned by Hyundai, which owns a 33.88% stake valued at just over US$6 billion. Kia in turn is a minority owner of more than twenty Hyundai subsidiaries ranging from 4.9% up to 45.37%, totaling more than US$8.3 billion.